366 related articles for article (PubMed ID: 20135697)
21. Nanoparticle-based delivery system for application of siRNA in vivo.
Wang Y; Li Z; Han Y; Liang LH; Ji A
Curr Drug Metab; 2010 Feb; 11(2):182-96. PubMed ID: 20359287
[TBL] [Abstract][Full Text] [Related]
22. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.
Babu A; Munshi A; Ramesh R
Drug Dev Ind Pharm; 2017 Sep; 43(9):1391-1401. PubMed ID: 28523942
[TBL] [Abstract][Full Text] [Related]
23. Delivery strategies for siRNA-mediated gene silencing.
Gilmore IR; Fox SP; Hollins AJ; Akhtar S
Curr Drug Deliv; 2006 Apr; 3(2):147-5. PubMed ID: 16611001
[TBL] [Abstract][Full Text] [Related]
24. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
25. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.
Sato Y; Matsui H; Sato R; Harashima H
J Control Release; 2018 Aug; 284():179-187. PubMed ID: 29936118
[TBL] [Abstract][Full Text] [Related]
26. Cellular delivery in vivo of siRNA-based therapeutics.
Aigner A
Curr Pharm Des; 2008; 14(34):3603-19. PubMed ID: 19075737
[TBL] [Abstract][Full Text] [Related]
27. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
28. Lipidic systems for in vivo siRNA delivery.
Wu SY; McMillan NA
AAPS J; 2009 Dec; 11(4):639-52. PubMed ID: 19757082
[TBL] [Abstract][Full Text] [Related]
29. Strategies and advances in nanomedicine for targeted siRNA delivery.
Nimesh S; Gupta N; Chandra R
Nanomedicine (Lond); 2011 Jun; 6(4):729-46. PubMed ID: 21718181
[TBL] [Abstract][Full Text] [Related]
30. Cationic lipids and polymers mediated vectors for delivery of siRNA.
Zhang S; Zhao B; Jiang H; Wang B; Ma B
J Control Release; 2007 Oct; 123(1):1-10. PubMed ID: 17716771
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
[TBL] [Abstract][Full Text] [Related]
32. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
33. Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy.
Yadav DN; Ali MS; Thanekar AM; Pogu SV; Rengan AK
Mol Pharm; 2022 Dec; 19(12):4506-4526. PubMed ID: 36409653
[TBL] [Abstract][Full Text] [Related]
34. siRNA delivery using nanocarriers - an efficient tool for gene silencing.
Khurana B; Goyal AK; Budhiraja A; Arora D; Vyas SP
Curr Gene Ther; 2010 Apr; 10(2):139-55. PubMed ID: 20353386
[TBL] [Abstract][Full Text] [Related]
35. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes.
Taratula O; Garbuzenko O; Savla R; Wang YA; He H; Minko T
Curr Drug Deliv; 2011 Jan; 8(1):59-69. PubMed ID: 21034421
[TBL] [Abstract][Full Text] [Related]
36. Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat.
Amadio M; Pascale A; Cupri S; Pignatello R; Osera C; D Agata V; D Amico AG; Leggio GM; Ruozi B; Govoni S; Drago F; Bucolo C
Pharmacol Res; 2016 Sep; 111():713-720. PubMed ID: 27475885
[TBL] [Abstract][Full Text] [Related]
37. Chitosan-based siRNA delivery systems.
Ragelle H; Vandermeulen G; Préat V
J Control Release; 2013 Nov; 172(1):207-218. PubMed ID: 23965281
[TBL] [Abstract][Full Text] [Related]
38. Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey.
Sarisozen C; Salzano G; Torchilin VP
Curr Pharm Biotechnol; 2016; 17(8):728-40. PubMed ID: 27033509
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in nanoparticle-mediated siRNA delivery.
Williford JM; Wu J; Ren Y; Archang MM; Leong KW; Mao HQ
Annu Rev Biomed Eng; 2014 Jul; 16():347-70. PubMed ID: 24905873
[TBL] [Abstract][Full Text] [Related]
40. Cuboplexes: Topologically Active siRNA Delivery.
Kim H; Leal C
ACS Nano; 2015 Oct; 9(10):10214-26. PubMed ID: 26390340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
